Intellia received RMAT designation from the FDA of nex-z for the treatment of patients with Transthyretin [ATTR] Amyloidosis with Cardiomyopathy. Global sales of the Transthyretin Amyloidosis market is expected to reach $12 billion by 2028. Long-term data from the phase 1/2 study, using NTLA-2002 for the treatment of patients with Hereditary Angioedema, expected in 2025.
Upgrading TSMC to 'Strong Buy' with a fair value of USD$246 per share due to its leading 2nm technology and market recovery potential. TSMC's 2nm production yields reached 60%, with Apple likely to be the first customer, maintaining a first-move advantage over Intel. TSMC's AI business is expected to grow by 100% year-over-year, contributing significantly to its revenue growth in FY25.
Artemis Gold Inc. receives a 'Buy' rating due to rising gold prices and the first precious metal pour at Blackwater mine. Blackwater mine's transition to production phase and robust growth prospects for precious metals bolster Artemis Gold's profit potential. Artemis Gold's stock price surged by 18.82%, outperforming the S&P 500, driven by positive sentiment and rising gold and silver prices.
Companies like Cheniere Energy have invested billions into infrastructure that chills, liquefies, and loads natural gas onto specialized tankers for export.
Amazon hasn't fallen for this many consecutive weeks since mid-2022. The post Amazon Stock Regains Some Ground But Still On Track For Sixth Straight Weekly Decline appeared first on Investor's Business Daily.
Vail Resorts' (MTN -2.23%) fiscal second quarter 2025 earnings call, held on March 10, 2025, revealed important insights for investors following the winter ski season. CEO Kirsten Lynch and CFO Angela Korch discussed financial results, operational performance, and strategic priorities that highlight the company's current position and future direction.
The owner of fashion brand Zara said store and online sales rose 4% at constant currency compared with the prior-year period.
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pain (NCP). The FDA's Fast Track designation is intended to accelerate the development and review of treatments for serious conditions with unmet medical needs, potentially expediting urcosimod's path to market if it is granted.
Campari's FY2024 report shows positive market reaction, driven by strong brand performance and strategic focus on efficiency and cost control under new CEO Simon Hunt. Despite challenges, Campari's Aperol and Espolòn brands exhibit robust growth, with Aperol's global expansion potential and Espolòn's rising U.S. market share. Tariffs pose a potential €100 million impact, but mitigation strategies and strong brand performance are expected to offset this burden.
Stella-Jones, a hidden gem in the Material sector, offers better margins and growth with its railway ties and utility poles business. Strong Q4'24 results with revenue up 6% YoY and EPS beating estimates; shares now present compelling value after a 24% decline. Strategic initiatives and a flexible balance sheet position Stella-Jones for continued growth, especially in utility poles and railway ties.
Lionsgate CFO James Barge said today the company is on track to close the separation of Lionsgate Studios and Starz by mid-to-late April. During a Q&A at the Morgan Stanley media conference he said the split has been in the works for a long time but was held up by one thing or another.
Rocket Lab is selling off after hours to continue a recent downtrend. Neutron remains on track, but a guidance miss and broader market sell-off make the short-term risky. The current price could offer value to long-term investors, but in the short-term, the stock could potentially experience volatility and further declines.